| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer | Chief Scientific Officer
1 company
Lyssikatos Joseph P is a Chief Scientific Officer at Enliven Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 16 sells.
Estimated insider holdings value: $33.4M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 12,500 | $21.40 | $267,457.50 | -1.3% | -6.5% | +111.7% | |
| Jun 3, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 7,500 | $20.03 | $150,219.75 | -0.8% | -4.4% | +64.8% | |
| May 19, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 5,000 | $16.31 | $81,533.50 | -0.5% | +17.2% | +138.4% | |
| May 2, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 7,500 | $20.05 | $150,390.64 | -0.4% | -8.3% | +103.3% | |
| Apr 21, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 5,000 | $16.07 | $80,365.82 | -0.2% | +34.8% | - | |
| Mar 19, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 12,500 | $20.61 | $257,575.00 | -1.2% | +4.4% | +43.8% | |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 847 | $30.00 | $25,412.54 | - | -24.2% | -26.2% | |
| Oct 9, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 51,145 | $28.11 | $1,437,585.19 | -1.2% | -15.4% | -24.5% | |
| Oct 7, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 10,229 | $27.54 | $281,664.00 | -0.5% | -12.3% | -26.7% | |
| Oct 1, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 527 | $27.54 | $14,512.10 | - | -13.9% | -23.8% |